Medexus Launches GRAFAPEX in US, Eyes $100M Revenue

Medexus Pharmaceuticals Inc ( (TSE:MDP) ) has shared an announcement.

Medexus Pharmaceuticals Inc has announced the commercial availability of GRAFAPEX (treosulfan) for Injection in the United States, marking a significant milestone for the company. This product, used as a preparative regimen for allogeneic hematopoietic stem cell transplantation, is expected to greatly enhance Medexus’s market position in the hemato-oncology space. The company anticipates that the annual revenue from GRAFAPEX in the U.S. could exceed $100 million within five years, reinforcing its strategic importance. This development comes shortly after receiving FDA approval and has already generated positive feedback from key institutions, indicating a strong potential impact on Medexus’s operations and revenue growth.

More about Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc is a pharmaceutical company operating in the healthcare industry. It focuses on developing, acquiring, and commercializing innovative pharmaceutical products primarily in North America. Medexus’s key market focus is in the hemato-oncology field, where it provides therapeutic solutions for conditions such as acute myeloid leukemia and myelodysplastic syndrome.

YTD Price Performance: -16.81%

Average Trading Volume: 112,819

Technical Sentiment Consensus Rating: Hold

Current Market Cap: C$92.28M

See more insights into MDP stock on TipRanks’ Stock Analysis page.